FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1396-1397 September 29, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lowsky, R. PubMed Citation

Myeloablative conditioning with high doses of chemotherapy before transplantation of allogeneic hematopoietic stem cells is a procedure that can cure hematologic malignant diseases, but its wide applicability is limited by a substantial death rate. Acute graft-versus-host disease (GVHD), which occurs in more than half the patients who undergo this treatment, is the main contributor to transplant-related mortality.

Recent experimental data indicate that acute GVHD develops in three phases^1,2: epithelial-cell injury caused by the conditioning regimen; activation of donor T-cell lymphocytes by antigens presented by the recipient's dendritic cells; and cell death induced by activated T cells, cytokines (such as . . . [Full Text of this Article]

Source Information

From the Service d'Hématologie–Greffe de Moelle, Hôpital Saint Louis, Université Paris VII, and INSERM Unité 728 — all in Paris.

This article has been cited by other articles:

• Kawase, T., Morishima, Y., Matsuo, K., Kashiwase, K., Inoko, H., Saji, H., Kato, S., Juji, T., Kodera, Y., Sasazuki, T., for The Japan Marrow Donor Program, (2007). High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110: 2235-2241 [Abstract] [Full Text]